Here, we describe the development of iNKT cells equipped with a dual, bispecific CAR against CD19 and CD133 as a potential off-the-shelf therapy for infant ALL, and investigate their activity against high-risk medullary and meningeal KMT2Ar-ALL. This evidence concerns the gene PROM1 and acute lymphoblastic leukemia.